You can buy or sell JNCE and other stocks, options, ETFs, and crypto commission-free!
Jounce Therapeutics, Inc. Common Stock, also called Jounce Therapeutics, is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Read More Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Jounce Therapeutics, Inc. (JNCE) Reports Q1 Loss, Misses Revenue Estimates
Jounce Therapeutics, Inc. (JNCE) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.40 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -22.58%. A quarter ago, it was expected that this company would post a loss of $0.35 per share when it actually produced a loss of $0.06, delivering a surprise of 82.86%. Over the last four quarters, the compa...
Markets InsiderMay 8
Jounce Therapeutics Reports First Quarter 2019 Financial Results
- New data from vopratelimab and JTX-8064 presented at AACR 2019 - - On track to initiate new Phase 2 studies of vopratelimab - - Ended the quarter with $173.2 million in cash, cash equivalents and investments - - Company to host conference call and webcast today at 8:00 AM ET - CAMBRIDGE, Mass., May 08, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patie...
Expected Aug 8, Pre-Market